INSYS Therapeutics (INSY) Bullish View Reiterated at Piper Jaffray Following Favorable Buprenorphine Data

Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy

PHOENIX, Aug. 24, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today reported that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint. 

The trial  was a multicenter, randomized, double-blind, multiple-dose, placebo-controlled study evaluating the efficacy and... More